Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2542-2548

  Al Abdely, Hail M ^a,b   Graybill, John R ^a,b   Bocanegra, Rosie ^a   Najvar, Laura ^a   Montalbo, Eleanor ^a   Regen, Steven L ^c   Melby, Peter C ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c LEHIGH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; KY 62; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LEISHMANIA; LEISHMANIA DONOVANI; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

EID: 0031680682     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2542     Document Type: Article

References (23)

1. Alvar, J., C. Cañavate, B. Gutiérrez-Solar, M. Jiménez, F. Laguna, R. López-Vélez, R. Molina, and J. Moreno. 1997. Leishmania and human immunodeficiency virus cointection: the first 10 years. Clin. Microbiol. Rev. 10:298-319.
2. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:684-703.
3. Bjorvatn, B., and F. A. Neva. 1979. Experimental therapy of mice infected with Leishmania tropica. Am. J. Trop. Med. Hyg. 28:480-485.
4. Castagnola, E., R. N. Davidson, P. Fiore, L. Tasso, G. Rossi, S. Mangraviti, L. di Martino, S. Scotti, A. Cascio, R. Pempinello, L. Gradoni, and R. Giacchino. 1996. Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 90:317-318.
5. Davidson, R. N., L. di Martino, L. Gradoni, R. Giacchino, G. B. Gaeta, R. Pempinello, S. Scotti, A. Cascio, E. Castagnola, A. Maisto, M. Gramiccia, D. di Caprio, R. J. Wilkinson, and A. D. Bryceson. 1996. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. 22:938-943.
6. Gasser, R. A., Jr., A. J. Magill, C. N. Oster, E. D. Franke, M. Grogl, and J. D. Berman. 1994. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin. Infect. Dis. 18:83-90.
7. Graybill, J. R., L. K. Najvar, A. Fothersill, T. Hardin, M. Rinaldi, C. Lambros, and S. L. Regen. 1998. KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis. Antomicrob. Agents Chemother. 42:147-150.
8. Melby, P. C., Y.-Z. Yang, J. Cheng, and W. Zhao. 1998. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66:18-27.
9. Mishra, M., U. K. Biswas, A. M. Jha, and A. B. Khan. 1994. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 344:1599-1600.
10. Mishra, M., U. K. Biswas, A. M. Jha, and A. B. Khan. 1992. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 340:1256-1257.
11. Momeni, A. Z., T. Jalaver, M. Emamjomeh, N. Bashardost, R. L. Ghassemi, M. Meghdadi, A. Javadi, and M. Aminjavaheri. 1996. Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Arch. Dermatol. 132:784-786.
12. Mortatti, R. C., and A. Henriques. 1990. Experimental cutaneous leishmaniasis by Leishmania amazonensis: course of fast-growth infection in the mouse ear. Parasitol. Res. 76:729-730.
13. Neal, R. A. 1964. Chemotherapy of cutaneous leishmaniasis: Leishmania tropica infection in mice. Ann. Trop. Med. Parasitol. 58:420-430.
14. Pearson, R. D., A. A. Manian, J. L. Harcus, D. Hall, and E. L. Hewlett. 1982. Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donavani. Science 217:369-371.
15. Pearson, R. D., and A. Q. Sousa. 1996. Clinical spectrum of leishmamasis. Clin. Infect. Dis. 22:1-13.
16. Pirson, P. B. Leclef, and A. Trouet. 1990. Activity of ketoconazole derivatives against Leishmania mexicana amazonensis within mouse peritoneal macrophages. Ann. Trop. Med. Parasitol. 84:133-139.
17. Ramos, H., E. Valdivieso, M. Gamargo, F. Dagger, and B. E. Cohen. 1996. Amphotericin B kills unicellular Leishmania by forming aqueous pores permeable to small cations and anions. J. Memhr. Biol. 152:65-75.
18. Rashid, J. R., K. M. Wasunna, G. S. Gachihi, P. M. Nyakundi, J. Mbugua, and G. Kirigi. 1994. The efficacy and safety of ketoconazole in visceral leishmaniasis. East Afr. Med. J. 71:392-395.
19. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-77.
20. Rosenthal, E., P. Marty, I. Poizot-Martin, J. Reynes, F. Pratlong, A. Lafeuillade, D. Jaubert, O. Boulat, J. Dereure, and F. Gambarelli. 1995. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans. R. Soc. Trop. Med. Hvg. 89:159-162.
21. Seaman, J., C. Boer, R. Wilkinson, J. de Jong, E. de Wilde, E. Sondorp, and R. Davidson. 1995. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin. Infect. Dis. 21:188-193
22. Walton, B. C. 1987. American cutaneous and mucocutaneous leishmaniasis, p. 644. In W. Peters and R. Killick-Kendrick (ed.), The leishmamases in biology and medicine, vol. II. Academic Press, London, United Kingdom.
23. Yarnasita, K., V. Janout, E. M. Bernard, D. Armstrong, and S. L. Regen. 1995. Micelle/monomer control over the membrane-disrupting properties of an amphiphilic antibiotic. J. Am. Chem. Soc. 117:6249-6253.